Changes in Lung Cancer Treatment as a Result of the Coronavirus Disease 2019 Pandemic | Lung Cancer | JAMA Oncology | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Views 3,985
    Citations 0
    Research Letter
    September 17, 2020

    Changes in Lung Cancer Treatment as a Result of the Coronavirus Disease 2019 Pandemic

    Author Affiliations
    • 1Cedars Cancer Center, McGill University Health Centre, Montreal, Quebec, Canada
    • 2Department of Internal Medicine, McGill University, Montreal, Quebec, Canada
    JAMA Oncol. Published online September 17, 2020. doi:10.1001/jamaoncol.2020.4408

    Patients with cancer have higher mortality rates from coronavirus disease 2019 (COVID-19),1-4 particularly those with lung cancer.5 Therefore, efforts are ongoing to limit exposure of these patients to the health care system. As a result, the COVID-19 pandemic has changed cancer care provision, but the extent and type of these changes are unknown. The goal of this study was to evaluate the changes in lung cancer treatment during the COVID-19 pandemic.

    We prospectively assessed the treatment plan of all patients seen in the thoracic oncology clinic at the McGill University Health Centre (MUHC) between March 2 and May 30, 2020. Inclusion criteria were a diagnosis of either non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). Those who had a diagnosis of COVID-19 were excluded. Primary end points were to describe the extent of changes in the treatment plan and qualify the types of changes observed as a direct result of the COVID-19 pandemic. Definition of change as a direct result of the pandemic was classified as such according to the patient’s medical record and not inferred. The study was determined to be exempt by the MUHC research ethics board and was conducted according to the declaration of Helsinki.